You can buy or sell PCSA and other stocks, options, and ETFs commission-free!
Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its product pipeline is PCS499, which is use for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on October 2, 2017 and is headquartered in Hanover, MD. The listed name for PCSA is Processa Pharmaceuticals, Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Mar 12, After Hours